EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Gene Correction Enhances Dopaminergic Cell Therapy in a Nonhuman Primate Model of Parkinson's Disease

Qing Yan, Chongchong Xu, Jiangmei Gao, Pu Wang, Qingling Wu, Ying Jin, Binyan Lu, Mu Li, Mingting Shao, Bihai Li, Zhenghui Su, Yijng Zhang und 18 weitere

Advanced Science · 2026

DOI: 10.1002/advs.76394 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Qing Yan und 29 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Key Laboratory of Animal Conservation and Resource Utilization, Guangdong Public Laboratory of Wild Animal Conservation and Utilization, In…. Hauptthemen laut MEDLINE: Parkinson Disease, Dopaminergic Neurons, Induced Pluripotent Stem Cells, Cell- and Tissue-Based Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, Guangdong Special Support Program for Health and Medical Talents.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human induced pluripotent stem cell (iPSC)‐derived dopaminergic progenitors offer a promising strategy for cell replacement in Parkinson's disease (PD), yet their long‐term efficacy and safety in primates remain underexplored. Here, we generated isogenic iPSC lines from a PD patient carrying compound LRRK2 mutations (R50H and M2397T) and used CRISPR/Cas9 and prime editing to correct these variants. Both mutant and gene‐corrected lines were differentiated into midbrain dopaminergic progenitors (DA‐NPCs), characterized in vitro, and transplanted bilaterally into the striatum of MPTP‐lesioned cynomolgus monkeys. Over 18 months, grafted cells survived, expressed TH and GIRK2, and exhibited mature electrophysiological properties. [ 1 8 F] DOPA PET imaging revealed restored dopamine synthesis in both grafting groups, with no statistically significant differences observed between mutant and gene‐corrected groups. Behavioral assessments showed sustained motor improvements and enhanced exploratory behavior. No tumor formation or adverse astrocytic response was observed, and systemic safety markers remained normal. These findings demonstrate that both mutant and corrected DA‐NPCs integrate and function in the primate brain. Our results support the feasibility of personalized regenerative therapies for genetic PD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseDopaminergic NeuronsInduced Pluripotent Stem CellsCell- and Tissue-Based TherapyLeucine-Rich Repeat Serine-Threonine Protein Kinase-2Genetic TherapyAnimalsMacaca fascicularisDisease Models, AnimalHumansMale

Stichwörter der Autor:innen

CRISPR/Cas9cell therapydopaminergic neuronsgene correctioninduced pluripotent stem cellsnonhuman primate modelparkinson's disease

Substanzen

Leucine-Rich Repeat Serine-Threonine Protein Kinase-2

Autor:innen und Institutionen

  • Guangdong Key Laboratory of Animal Conservation and Resource Utilization, Guangdong Public Laboratory of Wild Animal Conservation and Utilization, Institute of Zoology, Guangdong Academy of Sciences, Guangzhou, Guangdon…
  • Zhuzhou Central Hospital, Zhuzhou, Hunan, China.
  • Guangzhou Regenverse Therapeutics Co., Ltd, Guangzhou, China.
  • Chengdu Wenjiang District People's Hospital, Chengdu, China.
  • State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, China.
  • Laboratory of Genomic and Precision Medicine, Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu, China.

ORCID-Profile: Jianhuan Chen

Förderung

  • National Key R&D Program of China
  • National Natural Science Foundation of China
  • Guangdong Special Support Program for Health and Medical Talents
  • GDAS' Project of Science and Technology Development
  • Key Science and Technology Project of Guangdong Province, China

Zitieren

APA

Yan, Q., Xu, C., Gao, J., Wang, P., Wu, Q., Jin, Y., Lu, B., Li, M., Shao, M., Li, B., Su, Z., Zhang, Y., Chen, J., An, H., Huang, M., Zhuang, X., Shen, Y., Wang, F., Xu, N., …, & Rao, J. (2026). Gene Correction Enhances Dopaminergic Cell Therapy in a Nonhuman Primate Model of Parkinson's Disease. Advanced Science. https://doi.org/10.1002/advs.76394

Vancouver

Yan Q, Xu C, Gao J, Wang P, Wu Q, Jin Y, et al. Gene Correction Enhances Dopaminergic Cell Therapy in a Nonhuman Primate Model of Parkinson's Disease. Advanced Science. 2026. doi:10.1002/advs.76394

BibTeX
@article{Yan2026,
  author = {Yan, Qing and Xu, Chongchong and Gao, Jiangmei and Wang, Pu and Wu, Qingling and Jin, Ying and Lu, Binyan and Li, Mu and Shao, Mingting and Li, Bihai and Su, Zhenghui and Zhang, Yijng and Chen, Jianhuan and An, Haojie and Huang, Mengyao and Zhuang, Xiaoji and Shen, Yuhui and Wang, Fenglin and Xu, Nana and Liu, Yiyan and Tang, Lei and Zhong, Xiuling and Zhong, Minyan and Chen, Jiecong and Wang, Zhenhuang and Luo, Xingrong and Liu, Sheng and Liu, RuiFeng and Zhang, Ling and Rao, Junhua},
  title = {Gene Correction Enhances Dopaminergic Cell Therapy in a Nonhuman Primate Model of Parkinson's Disease},
  journal = {Advanced Science},
  year = {2026},
  doi = {10.1002/advs.76394}
}
Kostenlos starten →